Summary Information:
Ovid Therapeutics Inc. Common Stock
NASDAQ:OVID


email
[email protected]
Our Main Pages
Stocks.TRoach.Net
TRoach.Org
TRoach.Net

NOTE: This page is for evaluation of a JFF Project.
This page is NOT updated on a regular basis.
Information on this page should NOT be used for investment purposes.


Ovid Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: OVID
SEC CIK: 0001636651
Phone: 212-776-4381
1460 BROADWAY
SUITE 15044
NEW YORK NY 10036
CEO: Jeremy Levin
Price when page updated: 3.109 Date: 2023-12-01
Company Website:
www.ovidrx.com

_Description: Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these disorders represent an attractive area for drug development as the understanding of the underlying biology has grown meaningfully over the last few years and today represents a substantial opportunity medically and commercially. Based on recent scientific advances in genetics and the biological pathways of the brain, Ovid aims to identify, discover and acquire novel compounds for the treatment of rare neurological disorders. Ovid has built a deep knowledge of such disorders, how to treat them and how to develop the clinically meaningful endpoints required for development of a compound in these disorders. As a result of this knowledge, Ovid has developed a robust pipeline of first-in-class compounds and programs. The company continues to execute on its strategy to build this pipeline by discovering, in-licensing and collaborating with leading biopharmaceutical companies and academic institutions. These pipeline programs include programs targeting rare epilepsies, Angelman syndrome and Fragile X syndrome, as well as early-stage programs into other monogenetic disorders. Ovid's most advanced pipeline programs include OV935 (soticlestat) in collaboration with Takeda and OV101 a δ-selective GABAA receptor agonist. Ovid's emerging pipeline programs include OV329, a small molecule GABA aminotransferase inhibitor for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms; OV882, a short hairpin RNA therapy approach for Angelman syndrome; OV815, a genetic therapy approach for KIF1A associated neurological disorder; and other non-disclosed researched targets.

IPO YEAR:
2017
Sector:
Health Care
Industry:
Biotechnology: Pharmaceutical Preparations
ADRTSO:

MarketCap:
219745833.00
Beta:
0.2469827426392338
52 Week High:
4.8
52 Week Low:
2.25
52 Week Change:
0.3677685950413223
Short Interest:

Short Date:

Shares Outstanding:
68092185
Dividend Rate:
0
Dividend Yield:
N/A
ExDividend Date:

Latest EPS:

Latest EPS Date:
10 Nov 2022
Float:
0
return on Equity:
-38.80%
Consensus EPS:

Number Of Estimates:

EPS Surprise Dollar:

Eps Surprise Percent:

EBITDA:
N/A
ttmEPS:
0
Revenue:
$1.445M
Gross Profit:

Cash:

Debt:

Institution Percent:
52.00%
Revenue Percent:

Revenue Per Employee:

Insider Percent:
2.50%
Return on Assets:
-34.90%
Return on Capital:

Profit Margin:
-
Price to Sales:
85.66
Price To Book:
0.77
Short Ratio:
2.73
PE Ratio:
0
Employees:
67
1Y Guesstimate
5.162:3.0:6




__The following are links to various summary and news pages for
__Ovid Therapeutics Inc. Common Stock [ OVID ].

__Note: Some Links might not have information for the company.


finance.Yahoo.com money.CNN.com NASDAQ research
WalletInvestor.com WSJ.com MarketBeat.com
finviz.com WallMine.com TheGlobeandMail.com
stock1010.com
NASDAQ - General Info SEC Insider Report Ownership Summary
Dividend History insiderbuyingselling.com
Facebook search Twitter search LinkedIn search
PRnewsWire.Com Google Forecast
tdameritrade.com BarChart.com
SeekingAlpha.com Markets.FT.com stocktwits.com
FinTel.io Ldmicro.com bloomberg.com
MarketWatch.com Reuters.com businessinsider.com
fool.com barrons.com zacks.com
GuruFocus.com Investing.com tipranks.com
thestreet.com nytimes.com earningswhispers.com
marketchameleon.com sunshineavenue.com stockinvest.us
stockanalysis.com stockconsultant.com ycharts.com
financialcontent.com docoh.com foxbusiness.com
cnbc.com investorsobserver.com tradingview.com
investopedia.com tmxmoney.com invest.cnyes.com
ask.com bing.com brave.com
duckduckgo.com ecosia.org excite.com
exalead.com gibiru.com hotbot.com
www.info.com infospace.com lycos.com
lukol.com metacrawler.com mojeek.com
becovi.com searx.thegpm.org search.com
swisscows.com webcrawler.com yahoo.com
yandex.com yep.com you.com




INDEX




Page design by: TRoach
Page Last Updated: 2023-12-01